Hepatic Encephalopathy  >>  Xifaxan (rifaximin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
NCT00364689: RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

Terminated
3
13
US
Rifaximin, Lactulose, Placebo
University of Miami, Bausch Health Americas, Inc.
Hepatic Encephalopathy
07/08
07/08
NCT00298038: A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

Completed
3
299
NA
Rifaximin, Xifaxan®, Placebo
Bausch Health Americas, Inc.
Hepatic Encephalopathy
08/08
08/08
NCT00686920: Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Completed
3
322
Canada, US
Rifaximin, Xifaxan®
Bausch Health Americas, Inc.
Hepatic Encephalopathy
12/10
12/10
NCT02086825: A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

Withdrawn
3
0
US
Rifaximin, Xifaxin, Lactulose
NYU Langone Health
Hepatic Encephalopathy
12/16
 
NCT04244877: Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility

Withdrawn
3
20
NA
Rifaximin, Xifaxan
MetroHealth Medical Center
Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth, Gastrointestinal Motility Disorder
05/23
12/23
NCT05754996: Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy

Recruiting
3
102
RoW
Nifuroxazide, Lactulose, Rifaximin 550Mg Tab
Cairo University
Hepatic Encephalopathy
12/24
12/24
RED-C-3131, NCT05071716: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Active, not recruiting
3
524
Canada, US, RoW
Rifaximin SSD, Placebo
Bausch Health Americas, Inc.
Hepatic Encephalopathy
09/25
09/25
RED-C-3132, NCT05297448: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Active, not recruiting
3
466
Europe, Canada, US, RoW
Rifaximin SSD, Placebo
Bausch Health Americas, Inc.
Hepatic Encephalopathy
01/26
01/26
NCT04161053: Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Recruiting
3
60
RoW
Rifaximin, Gastrobiotic, Trencedia, Nitazoxanide, Nanazoxid
Tanta University
Hepatic Encephalopathy
11/28
12/28

Download Options